Novel, in-vivo and in vitro data suggest that exenatide, a GLP-1 receptor agonist, may represent an ideal therapy for IIH through rapid reduction of CSF secretion at the choroid plexus, lowering ICP in addition to its weight loss properties. The gene discussed is GLP1R; the disease is pseudotumor cerebri.